Aptevo Therapeutics (APVO): Forecast Levels Chart
Aptevo Therapeutics (APVO) faces a liquidity shortage and the threat of delisting due to the instability of early tests. This price chart illustrates the dynamics of the asset, which is currently valued at 25.54. Aptevo Therapeutics develops specific tumor-targeting antibodies, leveraging the success of mipitamonig and the ADAPTIR system. High barriers to entry and patents on molecular architecture provide business protection before the FDA.
%20Consensus%20Target&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_APVO_-_Aptevo-Therapeutics_-_Consensus-Target "aptevotherapeutics.com - APVO Price Target Chart (period 07/04/2022 - 11/12/2026) | 👁️GURU.Markets👁️")
Analytical breakdowns for Aptevo Therapeutics (APVO)
- stock value and consensus price forecast:
- stock exchange capitalization data:
- balance sheet net asset value indicators:
- business debt structure and liquidity details:
Aggregate Debt to Equity Aptevo Therapeutics|APVO - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital aptevotherapeutics.com|APVO - Company Aggregate Debts|Debts to Book Capitalization Aptevo|APVO - Company Long-Term Debt|Company Short-Term Loans and Borrowings Aptevo Therapeutics|Quick Liquidity Indicator aptevotherapeutics.com
- financial results and valuation multiples details:
APVO - Net Profit|Projected Future Earnings Aptevo Therapeutics|APVO - Price to Earnings Ratio|Future Price to Earnings Multiple aptevotherapeutics.com|APVO - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Aptevo|APVO - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Aptevo Therapeutics|APVO - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months aptevotherapeutics.com|APVO - Net earnings per share growth this year|Earnings growth forecast for next year Aptevo Therapeutics
General company analysis:APVO Aptevo Therapeutics, Inc.
The assessment of Aptevo Therapeutics (APVO) financial stability depends directly on market confidence in the potential of the ADAPTIR platform to combat oncology. The consensus target price represents the weighted average fair value of the business as calculated by independent experts, allowing investors to track the dynamics of market expectations regarding the efficacy of the company's bispecific antibodies and its future fundamental results.
Competitors of Aptevo Therapeutics
Analyst Consensus Forecast argenx.com (ARGX)|Price Target Chart BioNTech BNTX|ABVX (Abivax SA) - Forecast Levels Chart|ADMA: Consensus Target|PTGX: Price Target Chart|Immunovant, Inc. (IMVT) - Price Target Chart|Average Forecast Price kiniksa.com (KNSA)|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|ACRS - Analyst Consensus Forecast|Kyverna Therapeutics (KYTX) - Price Target Chart|Forecast Levels Chart TLSA (tizianalifesciences.com)|Consensus Target CABA|VTYX (Ventyx Biosciences Inc.) - Analyst Forecast Prices|Analyst Consensus Forecast THTX|AVTX - Average Forecast Price|Eledon Pharmaceuticals - Consensus Target|agenusbio.com - Price Target Chart|CLYM - Price Target Chart|Average Forecast Price zurabio.com|ATYR (aTyr) - Consensus Target|Adagene Inc. - Fair Value Consensus|Consensus Target IMA|STTK (Shattuck Therapeutics) - Analyst Forecast Prices|Analyst Consensus Forecast EQ|CNTB (connectbiopharm.com) - Fair Value Consensus|Analyst Consensus Forecast IMUX (Immunic)|Atara Biotherapeutics, Inc. (ATRA) - Average Forecast Price|IFRX - Price Target Chart|Fair Value Consensus XFOR (x4pharma.com)|ACET: Analyst Consensus Forecast|Celularity (CELU) - Analyst Consensus Forecast|Price Target Chart INmune Bio Corp|Barinthus Biotherapeutics Corp - Forecast Levels Chart|Analyst Consensus Forecast KZR|SABS - Average Forecast Price|Akari Therapeutics Plc - Consensus Target|Analyst Consensus Forecast Enlivex Therapeutics Ltd ENLV|QTTB: Consensus Target|GeoVax Corp - Analyst Forecast Prices|EDSA: Analyst Consensus Forecast|IBIO - Analyst Median Target|CARM (Carisma Therapeutics Inc) - Analyst Consensus Forecast|Consensus Target XTL Biopharmaceuticals Ltd (XTLB)|Price Target Chart Bolt Biotherapeutics (BOLT)|Analyst Median Target hcwbiologics.com|Analyst Consensus Forecast AIM (AIM ImmunoTech)|Analyst Consensus Forecast Aditxt Inc. ADTX|GRI - Price Target Chart|Forecast Levels Chart XRTX|HIND (ReShape Lifesciences) - Consensus Target|REVB (Revelation Biosciences Corp) - Price Target Chart|Price Target Chart Indaptus Therapeutics|Average Forecast Price scinai.com SCNI|Price Target Chart CalciMedica, Inc. (CALI)|AFMD: Forecast Levels Chart|Analyst Consensus Forecast ALLK (Allakos)|Fair Value Consensus HOOK|IGM Bio - Analyst Consensus Forecast|ITOS - Analyst Consensus Forecast|Ocean Biomedical (OCEA) - Price Target Chart|TC BioPharm (Holdings) Plc - Fair Value Consensus|Price Target Chart Third Harmonic Bio, Inc
